ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-OR087

Correction of Anemia by Dapagliflozin in Patients with T2D

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Stefansson, Bergur V., AstraZeneca, Gothenburg, Sweden
  • L Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, Netherlands
  • Wheeler, David C., University College London, London, United Kingdom
  • Sjostrom, David, AstraZeneca, Gothenburg, Sweden
  • Greasley, Peter J., AstraZeneca, Gothenburg, Sweden
  • Sartipy, Peter, AstraZeneca, Gothenburg, Sweden
  • Correa-Rotter, Ricardo, Institutor Nacional de la Nutricion, Mexico City, Mexico
Background

Type 2 diabetes (T2D) is one of the most common causes of chronic kidney disease (CKD) and the most frequent cause of renal anemia. Most patients (pts) with T2D show no overt symptoms of renal impairment, consequently, unrecognized anemia is common. Increased hemoglobin (Hb) levels have been observed with dapagliflozin (DAPA) treatment. This study investigated the efficacy and safety of DAPA 10mg in pts with and without anemia at baseline.

Methods

This post-hoc analysis evaluated the effect of the sodium-glucose cotransporter 2 inhibitor, DAPA 10mg, on Hb over 24 weeks (w) across 14 placebo (PBO)-controlled studies in T2D pts with or without anemia (women Hb<12.0 g/dL; men Hb<13.0 g/dL).

Results

A total of 5324 pts were included, 700 (13%) pts had anemia at baseline. There were 1168 (22%) pts with CKD (eGFR<60 mL/min/1.73m2), 324 (28%) had anemia at baseline. As expected, pts with anemia vs those without anemia were older (mean age:63 vs 59y), had a longer duration of T2D (14 vs 9y) and more advanced CKD (mean eGFR: 66.3 vs 78.6 mL/min/1.73m2 and mean UACR: 274 vs 89 mg/g). Longitudinal repeated measures analysis showed an Hb increase at w 24 in the DAPA 10mg anemia and no-anemia subgroups (Fig.1A). Anemia: (Mean g/dL(SEM)[95% CI], DAPA 0.81(0.066)[0.68,0.93], PBO 0.28(0.067)[0.15,0.41]; difference vs PBO 0.53(0.076)[0.38,0.68]). No-anemia: (DAPA 0.56(0.017)[0.53,0.60] and PBO -0.20(0.018)[-0.23,-0.16]; Difference vs PBO 0.76(0.024)[0.72, 0.81]). DAPA 10mg corrected anemia in more pts than PBO; DAPA 10mg 52% vs PBO 26% (Fig.1B). Overall, DAPA 10mg was well tolerated.

Conclusion

Unrecognized anemia is common in pts with T2D. DAPA 10mg corrected anemia by increasing Hb over 24w and was well tolerated. This effect may be driven by a reduction in blood volume but the increase in Hb beyond w 4 may be explained by other mechanisms.

The effect of DAPA 10mg on Hb in pts with and without anemia over 24 weeks

Funding

  • Commercial Support